FDA AI Guidance 2025 Interactive Visualizer

Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios.

FDA AI Guidance 2025 Interactive Visualizer

Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios.
Cyntegrity logo – Risk-Based Quality Management Solutions

Making AI Regulation Understandable Across the Lifecycle

AI-enabled device software is no longer assessed at a single regulatory milestone. FDA’s 2025 guidance reflects a shift toward continuous oversight, where performance, safety, and governance must be demonstrated throughout the product lifecycle.


The FDA AI Guidance Interactive Visualizer translates this regulatory evolution into an accessible, visual format. It helps clinical, quality, and regulatory teams understand how ethical foundations, risk management, validation, and post-market monitoring fit together as a coherent regulatory expectation.

What You Can Do With the Visualizer

Explore regulatory expectations through interactive scenarios.

Follow the AI Lifecycle From Design to Post-Market Use

Trace how FDA expectations apply across design, validation, submission, monitoring, and model updates under a Total Product Lifecycle approach.

Assess Regulatory Risk and Decision Points

Interact with risk scenarios, submission decision trees, and update pathways to understand when changes may trigger regulatory action.

Interpret Transparency, Performance, and Governance Expectations

Explore explainability, data representativeness, cybersecurity threats, and model performance metrics that regulators expect to see documented and justified.

From Static Guidance to Applied Understanding

The visualizer is built directly on FDA’s 2025 AI guidance for AI-enabled device software functions. Rather than presenting regulatory text in isolation, it uses interactive visuals to demonstrate how principles such as transparency, bias mitigation, cybersecurity, and continuous learning operate together in practice.

 

By simulating lifecycle events, performance drift, and risk prioritization, the visualizer facilitates a more straightforward interpretation of regulatory intent and enables teams to anticipate oversight expectations before they become compliance issues.

What changes when AI oversight is treated as a lifecycle responsibility?
Explore how continuous monitoring and documented decision-making shape regulatory confidence over time.

Part of the eyesON Interactive Visualizer Series

The FDA AI Guidance Visualizer is part of Cyntegrity’s eyesON series—a collection of interactive tools designed to make complex regulatory and clinical concepts easier to explore, understand, and discuss.

 

These visualizers are offered as educational resources, helping clinical research and regulatory professionals build shared understanding around evolving expectations without adding operational burden. Explore More Interactive Visualizers…

Explore Our Visualizer

See how other datasets can sharpen signal awareness and decision-making.

Stay Informed with Us

Risk-based quality management in 2026

Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials....
Diagram illustrating the FDA Total Product Lifecycle (TPLC) management approach for AI and machine learning devices, showing a continuous cycle of design, validation, submission, monitoring, and update.

FDA AI Guidance 2025 Interactive Visualizer

Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios....

Media Inquiries

Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.

Let’s Talk RBQM @ SCOPE Summit! Visit us at Booth #615

Cyntegrity logo – Risk-Based Quality Management Solutions
Picture of Artem Andrianov, PhD

Artem Andrianov, PhD

CEO & Founder

Picture of Dr. Johann Proeve

Dr. Johann Proeve

Chief Scientific Officer

Picture of David Lacagnina

David Lacagnina

Chief Business Officer

Picture of Sven Cohadzic

Sven Cohadzic

Project Manager